Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Apr;7(4):e1001330.
doi: 10.1371/journal.ppat.1001330. Epub 2011 Apr 7.

SLO-1-channels of parasitic nematodes reconstitute locomotor behaviour and emodepside sensitivity in Caenorhabditis elegans slo-1 loss of function mutants

Claudia Welz  1 , Nina Krüger, Monika Schniederjans, Sandra M Miltsch, Jürgen Krücken, Marcus Guest, Lindy Holden-Dye, Achim Harder, Georg von Samson-Himmelstjerna
Affiliations

SLO-1-channels of parasitic nematodes reconstitute locomotor behaviour and emodepside sensitivity in Caenorhabditis elegans slo-1 loss of function mutants

Claudia Welz et al. PLoS Pathog. 2011 Apr.

Abstract

The calcium-gated potassium channel SLO-1 in Caenorhabditis elegans was recently identified as key component for action of emodepside, a new anthelmintic drug with broad spectrum activity. In this study we identified orthologues of slo-1 in Ancylostoma caninum, Cooperia oncophora, and Haemonchus contortus, all important parasitic nematodes in veterinary medicine. Furthermore, functional analyses of these slo-1 orthologues were performed using heterologous expression in C. elegans. We expressed A. caninum and C. oncophora slo-1 in the emodepside-resistant genetic background of the slo-1 loss-of-function mutant NM1968 slo-1(js379). Transformants expressing A. caninum slo-1 from C. elegans slo-1 promoter were highly susceptible (compared to the fully emodepside-resistant slo-1(js379)) and showed no significant difference in their emodepside susceptibility compared to wild-type C. elegans (p = 0.831). Therefore, the SLO-1 channels of A. caninum and C. elegans appear to be completely functionally interchangeable in terms of emodepside sensitivity. Furthermore, we tested the ability of the 5' flanking regions of A. caninum and C. oncophora slo-1 to drive expression of SLO-1 in C. elegans and confirmed functionality of the putative promoters in this heterologous system. For all transgenic lines tested, expression of either native C. elegans slo-1 or the parasite-derived orthologue rescued emodepside sensitivity in slo-1(js379) and the locomotor phenotype of increased reversal frequency confirming the reconstitution of SLO-1 function in the locomotor circuits. A potent mammalian SLO-1 channel inhibitor, penitrem A, showed emodepside antagonising effects in A. caninum and C. elegans. The study combined the investigation of new anthelmintic targets from parasitic nematodes and experimental use of the respective target genes in C. elegans, therefore closing the gap between research approaches using model nematodes and those using target organisms. Considering the still scarcely advanced techniques for genetic engineering of parasitic nematodes, the presented method provides an excellent opportunity for examining the pharmacofunction of anthelmintic targets derived from parasitic nematodes.

PubMed Disclaimer

Conflict of interest statement

Achim Harder is employed by BayerHealthCare AG, which is developing veterinary pharmaceuticals including antiparasiticdal drugs like emodepside. This study was performed as a collaborative research project between Bayer HealthCare AG and the Institute for Parasitology and Tropical Veterinary Medicine, Freie Universität Berlin as well as previously the Institute for Parasitology at the University of Veterinary Medicine, Hannover. Accordingly, both academic institutions received project specific reseach grants from Bayer HealthCare AG.

Figures

Figure 1
Figure 1. Phylogenetic tree of SLO-1 amino acid sequences and related potassium channels.
The tree was calculated using Neighbour Joining method. Numbers at the branches indicate bootstrap values (in %, 1000 replicates). The bar shows number of substitutions per mutation site. The selected sequences (GenBank accession numbers in brackets) are as follows: C. elegans SLO-1a (AAL28102); C. elegans SLO-1b (AAL28103); C. elegans SLO-1c (AAL28104); C. briggsae hypothetical protein CBG12923 (XP_001675579.1); A. caninum SLO-1 (EU828635); C. oncophora SLO-1 (EF494185); H. contortus SLO-1 (EF494184); Ixodes scapularis putative calcium-activated potassium channel (EEC10339.1); Cancer borealis calcium-activated potassium channel (AAZ80093.4); Manduca sexta calcium-activated potassium channel alpha subunit (AAT44358.1); Pediculus humanus corporis putative calcium-activated potassium channel alpha subunit (EEB13088.1); Drosophila melanogaster slowpoke, isoform P (NP_001014652.1); Tribolium castaneum predicted protein similar to slowpoke CG10693-PQ (XP_968651.2); Aplysia californica high conductance calcium-activated potassium channel (AAR27959.1); Xenopus laevis potassium large conductance calcium-activated channel, subfamily M, alpha member 1 (NP_001079159.1); Danio rerio novel calcium activated potassium channel (CAX13266.1); Trachemys scripta calcium-activated potassium channel (AAC41281.1); Gallus gallus calcium-activated potassium channel alpha subunit (AAC35370.1); Monodelphis domestica predicted protein similar to large conductance calcium-activated potassium channel subfamily M alpha member 1 (XP_001367795.1); Mus musculus mSlo (AAA39746.1); Homo sapiens potassium large conductance calcium-activated channel, subfamily M, alpha member 1, isoform CRA_d (EAW54600.1); Bos taurus BK potassium ion channel isoform C (AAK54354.1); Canis familiaris calcium-activated K+ channel, subfamily M subunit alpha-1 (Q28265.2); Strongylocentrotus. purpuratus predicted protein similar to calcium-activated potassium channel alpha subunit (XP_783726.2).
Figure 2
Figure 2. Behavioural phenotype of transgenic C. elegans.
(A) number of reversals in 3 min were counted on NGM agar without bacteria for N2 Bristol, slo-1(js379) and the indicated transgenic lines derived from slo-1(js379). All values are means + SD. An asterisk (*) marks significant differences to all other lines (p<0.001) determined by One-Way-ANOVA followed by Tukey's test. (B) number of body bends per minute counted on NGM agar without bacteria. One-Way-ANOVA revealed no significant differences between different lines. N2, N2 Bristol wild-type strain; js379, slo-1(js379) mutant strain; Cel-snb-1::Aca-slo-1, line expressing A. caninum slo-1 from the C. elegans snb-1 promoter; Cel-snb-1::Con-slo-1, line expressing C. oncophora slo-1 from the C. elegans snb-1 promoter; Cel-slo-1::Aca-slo-1, line expressing A. caninum slo-1 from the C. elegans slo-1 promoter; Cel-slo-1::Cel-slo-1, line expressing C. elegans slo-1 from the C. elegans slo-1 promoter; Aca-slo-1::Aca-slo-1, line expressing A. caninum slo-1 from the A. caninum slo-1 promoter; Con-slo-1::Con-slo-1, line expressing C. oncophora slo-1 under control of the C. oncophora slo-1 promoter.
Figure 3
Figure 3. Parasite SLO-1 expressed from C. elegans promoters recover emodepside susceptibility in resistant slo-1 loss-of-function mutants.
Body bend activity in percent (relative to the highest number of body bends in that group) of young adults after 24 h exposure to emodepside. Comparison of wild-type N2, emodepside-resistant strain slo-1(js379), and transformed slo-1(js379) lines. Error bars represent standard errors of the mean. Dots (•) represent transformed lines, squares (▪) N2 Bristol wild-type strain, triangles (▴) js379(slo-1) mutant strain. (A) Cel-snb-1::Aca-slo-1, line expressing A. caninum slo-1 from the C. elegans snb-1 promoter. (B) Cel-snb-1::Con-slo-1, line expressing C. oncophora slo-1 from the C. elegans snb-1 promoter. (C) Cel-slo-1::Aca-slo-1, line expressing A. caninum slo-1 from the C. elegans slo-1. (D) Cel-slo-1::Cel-slo-1, C. elegans slo-1 expressed from C. elegans slo-1 promoter.
Figure 4
Figure 4. Parasite SLO-1 expressed from parasite-derived slo-1 promoters partially recover emodepside susceptibility in resistant slo-1 loss-of-function mutants.
Body bend activity (relative to the highest number of body bends in each group) of young adults after 24 h exposure to emodepside. Comparison of wild-type N2, emodepside-resistant strain slo-1(js379), and transformed slo-1(js379) lines. Dots (•) represent Aca-slo-1::Aca-slo-1 lines (expressing A. caninum slo-1 from the putative A. caninum slo-1 promoter); inverted triangles (▾) Con-slo-1::Con-slo-1 lines (expressing C. oncophora slo-1 from the putative C. oncophora slo-1 promoter); squares (▪) N2 Bristol wild-type strain, triangles (▴) js379(slo-1) mutant strain.
Figure 5
Figure 5. Effect of penitrem A and emodepside on nematode locomotion.
(A) Migration of infective A. caninum larvae (relative to negative control without vehicle) through a 20 µm precision sieve after incubation in different concentrations of emodepside in presence or absence of penitrem A. (B) Body bend activity of C. elegans (relative to negative control without vehicle). (A, B) Negative control (black bar), without vehicle or substance; vehicle control (light grey bars), with 28 mM DMSO, 170 mM ethanol, and the indicated emodepside concentrations; 1 µM penitrem A (dark grey bars), with 1 µM penitrem A, 170 mM ethanol and the indicated emodepside concentrations. Error bars represent standard deviations. Asterisks mark a significant difference between vehicle controls and the experiments with 1 µM penitrem A at the same emodepside concentration (*** p<0.001) determined by One-Way-ANOVA followed by a Tukey's pairwise comparison.
See this image and copyright information in PMC

References

    1. Jasmer DP, Goverse A, Smant G. Parasitic nematode interactions with mammals and plants. Annu Rev Phytopathol. 2003;41:245–270. - PubMed
    1. Wolstenholme AJ, Fairweather I, Prichard R, Samson-Himmelstjerna G, Sangster NC. Drug resistance in veterinary helminths. Trends Parasitol. 2004;20:469–476. - PubMed
    1. De Clercq D, Sacko M, Behnke J, Gilbert F, Dorny P, et al. Failure of mebendazole in treatment of human hookworm infections in the southern region of Mali. Am J Trop Med Hyg. 1997;57:25–30. - PubMed
    1. Albonico M, Bickle Q, Ramsan M, Montresor A, Savioli L, et al. Efficacy of mebendazole and levamisole alone or in combination against intestinal nematode infections after repeated targeted mebendazole treatment in Zanzibar. Bull World Health Organ. 2003;81:343–52. - PMC - PubMed
    1. Reynoldson JA, Behnke JM, Pallant LJ, Macnish MG, Gilbert F, et al. Failure of pyrantel in treatment of human hookworm infections (Ancylostoma duodenale) in the Kimberley region of north west Australia. Acta Trop. 1997;68:301–12. - PubMed

Publication types

MeSH terms